Ir para o conteúdo principal

MeiraGTx (NASDAQ: MGTX) — Perfil da empresa, notícias e dados financeiros

Logo de MeiraGTx
MGTX MeiraGTx
MeiraGTx  primary media
Perfil da empresa

MeiraGTx

MeiraGTx (NASDAQ:MGTX) is a biotechnology company dedicated to developing cutting-edge gene therapy solutions for patients suffering from diseases of high unmet medical need. The primary focus of the company is on the development of treatments for eye diseases, salivary gland conditions, and neurodegenerative diseases. Throughout its operations, MeiraGTx aims to leverage its unique gene therapy platforms to create transformative treatments that can significantly improve the quality of life for patients worldwide. Their projects span from early discovery to late-stage development, emphasizing innovation, patient safety, and efficacy. By pursuing a deep understanding of genetic diseases, MeiraGTx's objective is to pioneer novel gene therapy solutions that address the root causes of these conditions, with the ultimate goal of delivering life-changing treatments to the patients and communities they serve.

Resumo

Public USParticipação acionária
2015Ano de fundação
422Funcionários
New York, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
New York City, US

Produtos e/ou serviços de MeiraGTx

  • Gene Therapy Development Platform: MeiraGTx develops methods for delivering gene therapies into patients' cells.
  • Gene Therapy for Rare Eye Diseases: They create gene therapies to treat inherited conditions affecting vision.
  • Gene Therapy for Blood Disorders: MeiraGTx researches gene therapies for diseases affecting blood clotting mechanisms.
  • Gene Therapy for Liver Diseases: They are developing gene therapies to address genetic conditions impacting the liver.
  • Preclinical Gene Therapy Research: MeiraGTx conducts early-stage research on gene therapies for various diseases.
  • Gene Therapy Pipeline Development: They have a pipeline of potential gene therapies in development for various conditions.

equipe executiva do MeiraGTx

  • Alexandria ForbesCEO, President & Director
  • Richard Brian GirouxCOO & CFO
  • Robert K. ZeldinChief Medical Officer
  • Robert J. WollinGeneral Counsel & Secretary
  • Stuart NaylorChief Scientific Officer of Ophthalmology
  • Michel MichaelidesHead of Clinical Ophthalmology
  • Christine Elise SheehySenior Vice President of Global Integration
  • Tim RandallSenior Vice President of Risk & Internal Controls
  • David RubinsteinSenior Vice President of Business Development
  • Tassos GeorgiadisSenior Vice President of Discovery & Preclinical Development

Principais indicadores financeiros

Resultados divulgados pela MeiraGTx , em USD.

Cap. de mercado
936,4 mi
Receita (TTM)
397,5 mi
P/L
11.2
LPA (diluído, TTM)
0.9
Dividend yield
—
Margem de lucro
19.9%
Receita e lucro anuais da MeiraGTx
Fim do ano fiscalReceitaResultado operacionalLucro líquido
81,4 mi-106 mi-114,2 mi
33,3 mi-164,2 mi-147,8 mi
14 mi-137,1 mi-84 mi
15,9 mi-116,4 mi-129,6 mi